Mitiglinide Calcium

Producers shown on SFDA

(Record date:30/08/2021）

Producers shown on EP

Not showing any

Producer:Jiangxi Jemincare Group Co., Ltd. was founded in 1999. Its pharmaceutical history can be traced back to the 1950s with 12,000 employees. Its headquarters is located in Nanchang, China. It has many industrial platforms and R&D institutes in Jiangxi, Beijing, Shanghai, Jiangsu and Zhejiang. 

Jiangxi Jemincare Group Co., Ltd. , established on January 15, 1999 and located in Yichun, Jiangxi Province, covers an area of 600 mu, with a construction area of about 120000 m2 and a total investment of 500 million yuan. It is a large high-tech pharmaceutical enterprise integrating scientific research, production, logistics and sales.
It has 10 dosage forms in line with the new GMP standard, with a total of 15 production lines. Among them, 6 sets of capsule filling equipment are manufactured by German Bosch Company and capsule packaging equipment are manufactured by Italian company. Automatic control has been realized between each unit,  with high production efficiency and low failure rate. It can produce 5 billion capsules, 300 million bags of granules, 2 billion tablets and 300 million oral liquids per year.

Staff size:500-599 persons

Registered capital:RMB 12 million

Producer:Yantai Zhengfang Pharmaceutical Co., Ltd., located in the beautiful coastal city of Yantai economic and Technological Development Zone, Yantai, is a modern pharmaceutical enterprise, mainly engaged in the development, production and sale of drugs for diabetes, cardiovascular, cerebrovascular, liver diseases, antiviral and other drugs. The company has 118 employees, of which professional and technical personnel account for more than 70%.

The company successfully passed the certification of the new version of GMP by the State Food and Drug Administration in May 2014, with an annual production capacity of 1 billion tablets, 1.35 billion capsules and 120 million bags of granules.

Staff size:About 100 persons

Registered capital:RMB 2 million

Producer:Dezhou Bocheng Pharmaceutical Co., Ltd., founded in 1986, has a pharmaceutical history of 34 years. It is a modern pharmaceutical and high-tech enterprise integrating drug R & D, production and sales in China, and has passed the national new version of GMP certification.

The company is committed to building a chronic disease health service platform for the elderly. At present, the series of chronic disease products represented by anweixin and anxinjian, which are popular in the market, are trusted by partners and patients with accurate curative effect and professional service. Follow up companies will take bone and joint pain, diabetes, hypertension pharmacy chronic disease category as the main line, launch a series of chronic disease products of retail pharmacy satisfaction, and create brand image of chronic disease management of the pharmaceutical company.

Staff size:50-99 persons

Registered capital:RMB 10 million

Producer:Dandong Tongyuan Pharmaceutical Co. has been renamed Liaoning Huarui United Pharmaceutical Co., Ltd., which was founded in 1987 and belongs to "northeast United Pharmaceutical Group". In 2002, the company was transformed into "Dandong Tongyuan Pharmaceutical Co., Ltd." the company is located in Dandong, the largest border city in China, with superior environment and convenient transportation. The company covers an area of 30000 square meters. The company has five workshops for ordinary solid preparations, cephalosporin solid preparations, cream tincture, water agent raw materials and traditional Chinese medicine extraction, with an annual production of 3 billion tablets, 4 billion capsules, 100 million bags of particles and 50 million pieces of ointment.

Staff size:50-99 persons

Registered capital:RMB 20.4082 million

Producer:Founded in 1995, Jiangsu Hansoh Pharmaceutical Group Co., Ltd.is a leading R &D-driven pharmaceutical company in China. The company was listed on the Hong Kong Stock Exchange in June 2019

We have set up effective in house sales force with therapeutic area focus and strong academic promotion capabilities. We have established world class facilities and a manufacturing quality management system that compares with the cGMP requirements in China,  the United States and Japan. Our manufacturing systems have obtained cGMP certifications from the U.S. FDA and the Japanese PMDA,  and we plan to leverage our strong track record and experience to obtain additional quality system certifications and adopt advanced standards for entries into overseas markets. Our manufacturing quality management system enables us to produce all of our pharmaceutical products and the majority of our active pharmaceutical ingredients (APIs) in-h ouse.

Staff size:9000-9999 persons

Registered capital:RMB 1 million

Staff size:1000-1999 persons

Registered capital:RMB 138.8 million

Producer:Lianyungang Runzhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary and API production base of Zhengda Tianqing Pharmaceutical Group, was established in 2010, covering an area of 206 mu. In 2012, it was recognized as a high-tech enterprise, mainly engaged in the R & D, production and sales of various chemical APIs.

At present, the company has 7 product production workshops, 4 pilot workshops for new products, 1 product development center, and 2 drug inspection centers, power workshops and warehouses. There are 52 products approved for listing in China, of which 16 are listed as high-tech products in Jiangsu Province, involving liver disease, tumor, cardiovascular, respiratory and other fields, with an annual production capacity of more than 100 tons.

With the continuous increase of product types and production scale, the economic benefits of the company have also increased year by year. In 2020, the sales revenue will reach 3.5 billion yuan, including 10 API products such as arotinib hydrochloride, magnesium isoglycyrrhizinate and Diammonium Glycyrrhizinate, forming a "product group with sales of more than 100 million". The company has passed FDA certification for "zero defect" twice, and 14 products passed GMP on-site inspection in 2020, indicating that the company's quality management is at a high level in the industry.

Staff size:1000-1999 persons

Registered capital:RMB 103 million 528 thousand and 805

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978